Butantan Institute

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Active:2

Completed:22

Trial Phases

4 Phases

Phase 1:7

Phase 2:3

Phase 3:7

+1 more phases

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (21 trials with phase data)• Click on a phase to view related trials

Phase 1

7 (33.3%)

Phase 3

7 (33.3%)

Phase 4

4 (19.0%)

Phase 2

3 (14.3%)

Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.

Phase 3

Not yet recruiting

Conditions: Dengue
Chikungunya

Interventions: Biological: Chikungunya (CHIKV) live attenuated vaccine (VLA1555)

First Posted Date: 2025-05-15

Last Posted Date: 2025-05-15

Lead Sponsor: Butantan Institute

Target Recruit Count: 900

Registration Number: NCT06973772

Locations: 🇧🇷
Centro Médico de São Francisco, Curitiba, PR, Brazil
🇧🇷
Centro de Pesquisa Inova, Toledo, PR, Brazil
🇧🇷
Hospital São Vicente de Paulo, Passo Fundo, RS, Brazil

and more 4 locations

Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)

Phase 3

Not yet recruiting

Conditions: Dengue

Interventions: Biological: Dengue 1,2,3,4 (attenuated) vaccine

First Posted Date: 2025-03-24

Last Posted Date: 2025-05-18

Lead Sponsor: Butantan Institute

Target Recruit Count: 997

Registration Number: NCT06891950

Locations: 🇧🇷
Centro de Pesquisa 1 (POA01): Hospital São Lucas - PUCRS, Porto Alegre, Rio Grande do Sul, Brazil

Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults

Phase 1

Not yet recruiting

Conditions: Avian Influenza A Virus

Interventions: Biological: Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) 7.5 mcg
Biological: Monovalent influenza vaccine type A (H5N8) 15 mcg
Other: Placebo

First Posted Date: 2025-02-24

Last Posted Date: 2025-05-18

Lead Sponsor: Butantan Institute

Target Recruit Count: 700

Registration Number: NCT06842173

Locations: 🇧🇷
Centro de Terapias Avançadas E Inovadoras - Ct Terapias/Ufmg, Belo Horizonte, Minas Gerais, Brazil
🇧🇷
Plátano Centro de Pesquisa Clínica LTDA, Recife, Pernambuco, Brazil
🇧🇷
Fundação de Apoio ao Ensino, Pesquisa e Assistência do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preta da Universidade de São Paulo - (Centro de Pesquisa Clínica - S), Serrana, São Paulo, Brazil

and more 2 locations

Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .

Phase 3

Active, not recruiting

Conditions: Influenza, Human

Interventions: Biological: Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage
Biological: Quadrivalent Influenza Vaccine (split virion, inactivated)
Biological: Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage

First Posted Date: 2023-03-22

Last Posted Date: 2025-01-31

Lead Sponsor: Butantan Institute

Target Recruit Count: 1373

Registration Number: NCT05779020

Locations: 🇧🇷
Instituto Auto Imune de Pesquisa e Educação Continuada - Real Hospital Português de Beneficência em Pernambuco (Site REC01), Recife, Pernambuco, Brazil
🇧🇷
Centro Oncológico de Roraima - CECOR (Site BVB-01), Boa Vista, Roraima, Brazil
🇧🇷
Centro de Pesquisas Clínicas da Universidade Federal de Sergipe (Site AJU01), Laranjeiras, Sergipe, Brazil

and more 7 locations

Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181-002)

Phase 2

Completed

Conditions: Dengue

Interventions: Biological: Butantan-DV
Biological: V181

First Posted Date: 2023-02-02

Last Posted Date: 2025-01-16

Lead Sponsor: Butantan Institute

Target Recruit Count: 1364

Registration Number: NCT05710224

Locations: 🇧🇷
Hospital Tacchini (Site 0006), Bento Gonçalves, Rio Grande Do Sul, Brazil
🇧🇷
Fundação Universidade de Caxias do Sul (FUCS) - Instituto de Pesquisas em Saúde (IPS) (Site 0017), Caxias do Sul, Rio Grande Do Sul, Brazil
🇧🇷
ONCOSITE - Centro de Pesquisa Clinica em Oncologia (Site 0005), Ijuí, Rio Grande Do Sul, Brazil

and more 11 locations

News

Dengue Vaccine Landscape Evolves: New Candidates Show Promise in Clinical Trials

6 months ago

Several dengue vaccine candidates are progressing through clinical trials, offering potential solutions for this widespread disease.